The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine

Behavioural Brain Research

Volumn 221, Issue 2, 2011, Pages 594-603

  Nyakas, Csaba ^a,b   Granic, Ivica ^b   Halmy, László G ^a   Banerjee, Pradeep ^c   Luiten, Paul G M ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Aging; Alzheimer's disease; Cholinergic system; Memantine

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[1-42]; CHOLINE ACETYLTRANSFERASE; GLUTAMIC ACID; MEMANTINE;

AGING; ALZHEIMER DISEASE; ARTICLE; ATTENTION; BEHAVIOR; BRAIN DEPTH STIMULATION; BRAIN PROTECTION; CELL ACTIVATION; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; DEGENERATION; DISEASE COURSE; DRUG ACTIVITY; EXCITOTOXICITY; FOREBRAIN; IN VIVO STUDY; LEARNING DISORDER; MEMORY; MENTAL PERFORMANCE; MICROGLIA; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SENILE PLAQUE;

AGING; AMYLOID BETA-PEPTIDES; ANIMALS; ATTENTION; AVOIDANCE LEARNING; CHOLINERGIC FIBERS; DEMENTIA; DISEASE MODELS, ANIMAL; HUMANS; MALE; MEMANTINE; MICROGLIA; NERVE DEGENERATION; PEPTIDE FRAGMENTS; PROSENCEPHALON; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 79955746908     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.05.033     Document Type: Article

References (77)

1. Alley G.M., Bailey J.A., Chen D., Ray B., Puli L.K., Tanila H., et al. Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J Neurosci Res 2010, 88:143-154.
2. Alvarez A., Alarcón R., Opazo C., Campos E.O., Muñoz F.J., Calderón F.H., et al. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 1998, 18:3213-3223.
3. Araujo D.M., Lapchak P.A., Robitaille Y., Gauthier S., Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 1988, 50:1914-1923.
4. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 2009, 118:167-179.
5. Arendt T., Bogl V., Arendt A., Tennstedt A. Loss of nefgaykemaurons in the nucleus basalis of Meynert in Alzheimer's disease. Paralysis agitans and Korsakoff's disease. Acta Neuropathol 1983, 61:101-108.
6. Arif M., Chikuma T., Ahmed M.M., Nakazato M., Smith M.A., Kato T. Effects of memantine on soluble Alphabeta(25-35)-induced changes in peptidergic and glial cells in Alzheimer's disease model rat brain regions. Neuroscience 2009, 164:1199-1209.
7. Auld D.S., Kornecook T.J., Bastianetto S., Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002, 68:209-245.
8. Barnes C.A., Danysz W., Parsons C.G. Effects of uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 1996, 8:939-945.
9. Bezprozvanny I., Mattson M.P. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 2008, 31:454-463.
10. Chen H.S., Lipton S.A. The chemical biology of clinically tolerated NMDA receptor antagonist. J Neurochem 2006, 97:1611-1626.
11. Claassen J.A., Jansen R.W. Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis. J Gerontol A: Biol Sci Med Sci 2006, 61:267-271.
12. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 2002, 277:32046-32053.
13. De Felice F.G., Velasco P.T., Lambert M.P., Viola K., Fernandez S.J., Ferreira S.T., et al. Abeta oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007, 282:11590-11601.
14. De Vos K.J., Grierson A.J., Ackerley S., Miller C.C. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci 2008, 31:151-173.
15. Falzone T.L., Stokin G.B., Lillo C., Rodrigues E.M., Westerman E.L., Williams D.S., et al. Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects. J Neurosci 2009, 29:5758-5767.
16. Fodero L.R., Mok S.S., Losic D., Martin L.L., Aguilar M.I., Barrow C.J., et al. Alpha7-nicotinic acetylcholine receptors mediate an Abeta(1-42)-induced increase in the level of acetylcholinesterase in primary cortical neurones. J Neurochem 2004, 88:1186-1193.
17. Francis P.T. Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine. Curr Mol Pharmacol 2009, 2:77-82.
18. Gaykema R.P., Gaál G., Traber J., Hersh L.B. Luiten PG The basal forebrain cholinergic system: efferent and afferent connectivity and long-term effects of lesions. Acta Psychiatr Scand 1991, 366:14-26.
19. Gaykema R.P., Luiten P.G., Nyakas C., Traber J. Cortical projection patterns of the medial septum-diagonal band complex. J Comp Neurol 1990, 293:103-124.
20. Gaykema R.P., Nyakas C., Horvath E., Hersh L.B., Majtenyi C., Luiten P.G. Cholinergic fiber aberrations in nucleus basalis lesioned rat and Alzheimer's disease. Neurobiol Aging 1992, 13:441-448.
21. Gaykema R.P., van der Kuil J., Hersh L.B., Luiten P.G. Patterns of direct projections from the hippocampus to the medial septum-diagonal band complex: anterograde tracing with Phaseolus vulgaris leucoagglutinin combined with immunohistochemistry of choline acetyltransferase. Neuroscience 1991, 43:349-360.
22. Goñi-Oliver P, Avila J, Hernández F. Memantine inhibits calpain-mediated truncation of GSK-3 induced by NMDA: implications in Alzheimer's disease. J Alzheimers Dis; in press.
23. Granic I, Masman MF, Mulder KC, Nijholt IM, Naude PJ, de Haan A, Borbély E, Penke B, Luiten PG, Eisel UL. LPYFDa neutralizes amyloid-beta-induced memory impairment and toxicity. J Alzheimers Dis; in press.
24. Harkany T., Abrahám I., Timmerman W., Laskay G., Tóth B., Sasvári M., et al. Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 2000, 12:2735-2745.
25. Harkany T., Penke B., Luiten P.G. beta-Amyloid excitotoxicity in rat magnocellular nucleus basalis. Effect of cortical deafferentation on cerebral blood flow regulation and implications for Alzheimer's disease. Ann NY Acad Sci 2000, 903:374-386.
26. Horvath K.M., Abrahám I.M., Harkany T., Meerlo P., Bohus B.G., Nyakas C., et al. Postnatal treatment with ACTH-(4-9) analog ORG 2766 attenuates N-methyl-d-aspartate-induced excitotoxicity in rat nucleus basalis in adulthood. Eur J Pharmacol 2000, 405:33-42.
27. Hogyes E., Nyakas C., Kiliaan A., Farkas T., Penke B., Luiten P.G.M. Neuroprotective effect of developmental docosahexaenoic acid supplement against excitotoxic brain damage in infant rats. Neuroscience 2003, 119:999-1012.
28. Hu L., Wong T.P., Côté S.L., Bell K.F., Cuello A.C. The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in Alzheimer's disease-like transgenic mice. Neuroscience 2003, 121:421-432.
29. Inestrosa N.C., Alvarez A., Calderón F. Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid beta-peptide into Alzheimer's filaments. Mol Psychiatr 1996, 1:359-361.
30. Kása P., Rakonczay Z., Gulya K. The cholinergic system in Alzheimer's disease. Prog Neurobiol 1997, 52:511-535.
31. Kasa P., Papp H., Kasa P., Torok I. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme-positive structures in the human and rat brain. Neuroscience 2000, 101:89-100.
32. Kelly B.L., Ferreira A. Bbeta-amyloid-induced dynamin 1 degradation is mediated by N-methyl-d-aspartate receptors in hippocampal neurons. J Biol Chem 2006, 281:28079-28089.
33. Kornhuber J., Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-d-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 1995, 195:137-139.
34. LaFerla F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 2002, 3:862-872.
35. Lipton S.A. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005, 2:155-165.
36. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006, 5:160-170.
37. Lipton S.A. Pathologically-activated therapeutics for neuroprotection. Nat Rev Neurosci 2007, 8:803-808.
38. Luiten P.G.M., Douma E.A., Van der Zee E.A., Nyakas C. Neuroprotection against NMDA induced cell death in rat nucleus basalis by Ca2+ antagonist nimodipine, influence of aging and developmental drug treatment. Neurodegeneration 1995, 4:307-314.
39. Luiten P.G., Gaykema R.P., Traber J., Spencer D.G. Cortical projection patterns of magnocellular basal nucleus subdivisions as revealed by anterogradely transported Phaseolus vulgaris leucoagglutinin. Brain Res 1987, 413:229-250.
40. Machová E., Jakubík J., Michal P., Oksman M., Iivonen H., Tanila H., et al. Impairment of muscarinic transmission in transgenic APPswe/PS1dE9 mice. Neurobiol Aging 2008, 29:368-378.
41. Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, Parsons CG, Gupta S, Banerjee P, Laferla FM. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol 176; in press.
42. Masliah E., Alford M., Adame A., Rockenstein E., Galasko D., Salmon D., et al. Abeta1-42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD. Neurology 2003, 61:206-211.
43. Masliah E., Alford M., Mallory M., Rockenstein E., Moechars D., Van Leuven F. Abnormal glutamate transport function in mutant amyloid precursor protein transgenic mice. Exp Neurol 2000, 163:381-387.
44. Masliah E., Mallory M., Hansen L., Alford M., Albright T., DeTeresa R., et al. Patterns of aberrant sprouting in Alzheimer's disease. Neuron 1991, 6:729-739.
45. Melo J.B., Agostinho P., Oliveira C.R. Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neurosci Res 2003, 45:117-127.
46. Mesulam M.-M., Mufson E.J., Rogers J. Age-related shrinkage of cortically projecting cholinergic neurons: a selective effect. Ann Neurol 1987, 22:31-36.
47. Minkeviciene R., Banerjee P., Tanila H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2004, 311:677-682.
48. Minkeviciene R., Banerjee P., Tanila H. Cognition-enhancing and anxiolytic effects of memantine. Neuropharmacology 2008, 54:1079-1085.
49. Molnár Z., Soós K., Lengyel I., Penke B., Szegedi V., Budai D. Enhancement of NMDA responses by beta-amyloid peptides in the hippocampus in vivo. Neuroreport 2004, 15:1649-1652.
50. Mufson E.J., Ginsberg S.D., Ikonomovic M.D., DeKosky S.T. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 2003, 26:233-242.
51. Nimmrich V., Szabo R., Nyakas C., Granic I., Reymann K.G., Schröder U.H., et al. Inhibition of calpain prevents N-methyl-d-aspartate-induced degeneration of the nucleus basalis and associated behavioral dysfunction. J Pharmacol Exp Ther 2008, 327:343-352.
52. Nitsch R.M., Slack B.E., Wurtman R.J., Growdon J.H. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992, 258:304-307.
53. Nyakas C., Felszeghy K., Szabó R., Keijser J.N., Luiten P.G., Szombathelyi Z., et al. Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. CNS Neurosci Ther 2009, 15:89-99.
54. Nyakas C., Markel E., Bohus B., Schuurman T., Luiten P.G. Protective effect of the calcium antagonist nimodipine on discrimination learning deficits and impaired retention behavior caused by prenatal nitrite exposure in rats. Behav Brain Res 1990, 38:69-76.
55. Onorato M., Mulvihill P., Connolly J., Galloway P., Whitehouse P., Perry G. Alteration of neuritic cytoarchitecture in Alzheimer disease. Prog Clin Biol Res 1989, 317:781-789.
56. Paxinos G., Watson S{cyrillic}. The Rat Brain in Stereotaxic Coordinates 1986, Academic Press, San Diego. 2nd ed.
57. Perry E., Walker M., Grace J., Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness?. Trends Neurosci 1999, 22:273-280.
58. Pigino G., Morfini G., Atagi Y., Deshpande A., Yu C., Jungbauer L., et al. Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta. Proc Natl Acad Sci USA 2009, 106:5907-5912.
59. Rammes G., Rupprecht R., Ferrari U., Zieglgänsberger W., Parsons C.G. The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 2001, 306:81-84.
60. Ray B, Banerjee PK, Greig NH, Lahiri DK. Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (Abeta) peptide in the human neuroblastoma cells. Neurosci Lett; in press.
61. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius H.J. Memantine in moderate-to-severe Alzheimer's disease. N Eng J Med 2003, 348:1333-1341.
62. Schliebs R., Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 2006, 113:1625-1644.
63. Shah S.B., Nolan R., Davis E., Stokin G.B., Niesman I., Canto I., et al. Examination of potential mechanisms of amyloid-induced defects in neuronal transport. Neurobiol Dis 2009, 36:11-25.
64. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007, 27:2866-2875.
65. Shi Q., Hu X., Prior M., Yan R. The occurrence of aging-dependent reticulon 3 immunoreactive dystrophic neurites decreases cognitive function. J Neurosci 2009, 29:5108-5115.
66. Stokin G.B., Lillo C., Falzone T.L., Brusch R.G., Rockenstein E., Mount S.L., et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005, 307:1282-1288.
67. Talesa V.N. Acetylcholinesterase in Alzheimer's disease. Mech Ageing Dev 2001, 122:1961-1969.
68. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., Gergel I. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: a randomized control trial. JAMA 2004, 291:317-324.
69. Van der Zee E.A., Luiten P.G. Muscarinic acetylcholine receptors in the hippocampus, neocortex and amygdala: a review of immunocytochemical localization in relation to learning and memory. Prog Neurobiol 1999, 58:409-471.
70. Van der Zee E.A., Matsuyama T., Strosberg A.D., Traber J., Luiten P.G. Demonstration of muscarinic acetylcholine receptor-like immunoreactivity in the rat forebrain and upper brainstem. Histochemistry 1989, 92:475-485.
71. Walsh D.M., Selkoe D.J. Abeta oligomers-a decade of discovery. J Neurochem 2007, 101:1172-1184.
72. Wenk G.L. Neuropathologic changes in Alzheimer's disease: potential targets for treatment. J Clin Psychiatry 2006, 67(Suppl. 3):3-7.
73. Wenk G.L., Parsons C.G., Danysz W. Potential role of N-methyl-d-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol 2006, 17:411-424.
74. Wenk G.L., Zajaczkowski W., Danysz W. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B infusion of (+)-MK-801 and memantine: contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Behav Brain Res 1997, 83:129-133.
75. Woolf N.J. Cholinergic systems in mammalian brain and spinal cord. Progr Neurobiol 1991, 37:475-524.
76. Wu H.M., Tzeng N.S., Qian L., Wei S.J., Hu X., Chen S.H., et al. Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation. Neuropsychopharmacology 2009, 34:2344-2357.
77. Züchner T., Perez-Polo J.R., Schliebs R. Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling. J Neurosci Res 2004, 77:250-257.